ReviewMedicine2025
Advances in the study and treatment of glucocorticoid osteoporosis: A review.
Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of CD8Frontiers in immunology · 2026Pooled it
- Differential Effects of Psychogenic Stress on Bone Morphology and Metabolism in Wistar Rats.Journal of bone metabolism · 2026Article
- Dexamethasone reduces osteogenic potential through suppressing retinoic acid signaling via NF-κB/CYP26B1 axis in mesenchymal stem cells.Stem cell research & therapy · 2026Article
- Long-term enoxaparin use and osteoporosis risk: a real-world cohort study with integrative computational and network toxicology approaches.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the widespread application of glucocorticoids in the medical field has led to a notable rise in the incidence of glucocorticoid-induced osteoporosis (GIOP). Currently, glucocorticoid-induced osteoporosis has emerged as the third leading cause of osteoporosis, following senile osteoporosis and postmenopausal osteoporosis. Scientific investigations have demonstrated that glucocorticoids exert a dual-pronged negative impact on bone metabolism. On one hand, glucocorticoids inhibit osteoblasts proliferation, trigger osteoblasts apoptosis, and undermine their osteogenic potential. On the other hand, glucocorticoids enhance osteoclasts proliferation and extend osteoclasts lifespan. Additionally, glucocorticoids can indirectly impede osteogenic differentiation by disrupting the balance of relevant cytokines and compromising the blood supply to bone tissue. This article is a comprehensive review of the latest research findings and treatment advances in the field of glucocorticoid-induced osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.